WO2012068519A3 - Markers associated with response to activated protein c administration, and uses thereof - Google Patents

Markers associated with response to activated protein c administration, and uses thereof Download PDF

Info

Publication number
WO2012068519A3
WO2012068519A3 PCT/US2011/061494 US2011061494W WO2012068519A3 WO 2012068519 A3 WO2012068519 A3 WO 2012068519A3 US 2011061494 W US2011061494 W US 2011061494W WO 2012068519 A3 WO2012068519 A3 WO 2012068519A3
Authority
WO
WIPO (PCT)
Prior art keywords
activated protein
response
administration
markers associated
agent
Prior art date
Application number
PCT/US2011/061494
Other languages
French (fr)
Other versions
WO2012068519A2 (en
Inventor
Francis Hugh Wellman
Alexandra Mancini
James Russell
Mauricio Neira
Original Assignee
Sirius Genomics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sirius Genomics Inc. filed Critical Sirius Genomics Inc.
Publication of WO2012068519A2 publication Critical patent/WO2012068519A2/en
Publication of WO2012068519A3 publication Critical patent/WO2012068519A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Abstract

The present invention includes and provides SNP biomarkers and methods for determining the effectiveness of treatment of immunological disorders, e.g. sepsis, with an anti - inflammatory agent or an anti - coagulant agent, e.g. activated Protein C. Included are materials such as nucleic acid molecules capable to detecting genetic polymorphisms that are predictive of an improved response to an anti - inflammatory agent or an anti - coagulant agent.
PCT/US2011/061494 2010-11-19 2011-11-18 Markers associated with response to activated protein c administration, and uses thereof WO2012068519A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US41568810P 2010-11-19 2010-11-19
US61/415,688 2010-11-19
US201161440187P 2011-02-07 2011-02-07
US61/440,187 2011-02-07
US201161446405P 2011-02-24 2011-02-24
US61/446,405 2011-02-24

Publications (2)

Publication Number Publication Date
WO2012068519A2 WO2012068519A2 (en) 2012-05-24
WO2012068519A3 true WO2012068519A3 (en) 2012-10-04

Family

ID=45099206

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/061494 WO2012068519A2 (en) 2010-11-19 2011-11-18 Markers associated with response to activated protein c administration, and uses thereof

Country Status (1)

Country Link
WO (1) WO2012068519A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10323289B2 (en) * 2017-06-26 2019-06-18 Institut Pasteur Treatments to eliminate HIV reservoirs and reduce viral load
CN113293214A (en) * 2021-06-17 2021-08-24 深圳华因康基因科技有限公司 Primer probe for detecting amplification of neuroblastoma recurrence transfer gene WNT2 and application thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006136033A1 (en) * 2005-06-23 2006-12-28 The University Of British Columbia Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy
US20070031847A1 (en) * 2003-03-10 2007-02-08 Applera Corporation Genetic polymorphisms associated with stenosis, methods of detection and uses thereof
US20070269827A1 (en) * 2006-05-18 2007-11-22 Oklahoma Medical Research Foundation Predicting and Diagnosing Patients With Autoimmune Disease
WO2007140625A1 (en) * 2006-06-09 2007-12-13 The University Of British Columbia Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects
WO2008098377A1 (en) * 2007-02-16 2008-08-21 The University Of British Columbia Serpine1 polymorphisms are predictive of response to activated protein c administration and risk of death
WO2009033282A1 (en) * 2007-09-10 2009-03-19 The University Of British Columbia Mitogen-activated protein kinase kinase kinase 14 (map3k14) polymorphisms as indicators of subject outcome in critically 111 subjects
EP2085486A1 (en) * 2008-02-01 2009-08-05 Assistance Publique - Hopitaux de Paris Methods and kits for the rapid determination of patients at high risk of death during septic shock

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2540122B1 (en) 1983-01-27 1985-11-29 Centre Nat Rech Scient NOVEL COMPOUNDS COMPRISING A SEQUENCE OF OLIGONUCLEOTIDE LINKED TO AN INTERCALATION AGENT, THEIR SYNTHESIS PROCESS AND THEIR APPLICATION
US5270040A (en) 1985-02-08 1993-12-14 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US5550036A (en) 1986-04-09 1996-08-27 Eli Lilly And Company Method for co-amplification of human protein C genes in human cells
US6270961B1 (en) 1987-04-01 2001-08-07 Hyseq, Inc. Methods and apparatus for DNA sequencing and DNA identification
US4992373A (en) 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US5196322A (en) 1987-12-28 1993-03-23 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
US4988167A (en) 1988-08-10 1991-01-29 Fergason James L Light blocking and vision restoration apparatus with glint control
US5128247A (en) 1989-08-14 1992-07-07 Board Of Regents, The University Of Texas System Methods for isolation of nucleic acids from eukaryotic and prokaryotic sources
US5358932A (en) 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
CA2071630C (en) 1989-12-29 2000-02-22 Donald C. Foster Hybrid protein c
US5270178A (en) 1990-02-23 1993-12-14 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
IL97311A0 (en) 1990-02-23 1992-05-25 Lilly Co Eli Vectors and compounds for expression of glycosylation mutants of human protein c
US5130423A (en) 1990-07-13 1992-07-14 Microprobe Corporation Non-corrosive compositions and methods useful for the extraction of nucleic acids
AT395596B (en) 1991-06-20 1993-01-25 Immuno Ag METHOD FOR PRODUCING ACTIVATED PROTEIN C
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
US5618714A (en) 1993-12-15 1997-04-08 Eli Lilly And Company Methods for producing protein C
US5705333A (en) 1994-08-05 1998-01-06 The Regents Of The University Of California Peptide-based nucleic acid mimics(PENAMS)
WO1996041810A1 (en) 1995-06-08 1996-12-27 Progen Industries Limited Method and apparatus for dna extraction
US5945515A (en) 1995-07-31 1999-08-31 Chomczynski; Piotr Product and process for isolating DNA, RNA and proteins
US5801115A (en) 1995-09-05 1998-09-01 Kataleuna Gmbh Catalyst composition and methods for using and preparing same
US5837843A (en) 1996-11-08 1998-11-17 Oklahoma Medical Research Foundation Modified protein C
JP3756313B2 (en) 1997-03-07 2006-03-15 武 今西 Novel bicyclonucleosides and oligonucleotide analogues
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
KR100564189B1 (en) 1997-04-28 2006-03-27 일라이 릴리 앤드 캄파니 Improved Methods for Processing Activated Protein ?
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
JP3888807B2 (en) 1999-08-06 2007-03-07 凸版印刷株式会社 Gene detection method, detection apparatus, and detection chip
US6841371B2 (en) 2000-02-02 2005-01-11 Eli Lilly And Company Protein C derivatives
WO2001059084A1 (en) 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives
EP1328622A2 (en) 2000-10-18 2003-07-23 Maxygen Aps Protein c or activated protein c-like molecules
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
JP2004527239A (en) 2001-03-02 2004-09-09 テイ・エイ・シー・スロムボシス・アンド・コアグラシヨン・エイ・ビー Protein C mutant
JP2005518801A (en) 2002-03-01 2005-06-30 テイ・エイ・シー・スロムボシス・アンド・コアグラシヨン・アクテイエボラーク Recombinant protein C variant
AU2003213146A1 (en) 2002-03-08 2003-09-22 Eli Lilly And Company Activated protein c formulations
US6872530B2 (en) 2002-04-24 2005-03-29 Spectrumedix, Llc Method for determining the presence of DNA variants using peptide nucleic acid probes

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070031847A1 (en) * 2003-03-10 2007-02-08 Applera Corporation Genetic polymorphisms associated with stenosis, methods of detection and uses thereof
WO2006136033A1 (en) * 2005-06-23 2006-12-28 The University Of British Columbia Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy
US20070269827A1 (en) * 2006-05-18 2007-11-22 Oklahoma Medical Research Foundation Predicting and Diagnosing Patients With Autoimmune Disease
WO2007140625A1 (en) * 2006-06-09 2007-12-13 The University Of British Columbia Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects
WO2008098377A1 (en) * 2007-02-16 2008-08-21 The University Of British Columbia Serpine1 polymorphisms are predictive of response to activated protein c administration and risk of death
WO2009033282A1 (en) * 2007-09-10 2009-03-19 The University Of British Columbia Mitogen-activated protein kinase kinase kinase 14 (map3k14) polymorphisms as indicators of subject outcome in critically 111 subjects
EP2085486A1 (en) * 2008-02-01 2009-08-05 Assistance Publique - Hopitaux de Paris Methods and kits for the rapid determination of patients at high risk of death during septic shock

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NISHIDA NAO ET AL: "Evaluating the performance of Affymetrix SNP Array 6.0 platform with 400 Japanese individuals", BMC GENOMICS, BIOMED CENTRAL, LONDON, GB, vol. 9, no. 1, 22 September 2008 (2008-09-22), pages 431, XP021042170, ISSN: 1471-2164, DOI: 10.1186/1471-2164-9-431 *

Also Published As

Publication number Publication date
WO2012068519A2 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
WO2012050975A3 (en) Novel circular mammalian rna molecules and uses thereof
WO2013130512A3 (en) Methods and uses for molecular tags
DK2089343T3 (en) Click chemistry for the preparation of reporter molecules
WO2009151691A3 (en) Genetic polymorphisms associated wiith venous thrombosis, methods of detection and uses thereof
WO2009105680A3 (en) Genetic polymorphisms associated with stroke, methods of detection and uses thereof
WO2012051386A3 (en) Reagent storage in an assay device
BR112012022210A2 (en) isolated antibody or its immunoreactive fragment, nucleic acid molecule, pharmaceutical composition, and use of the isolated antibody
WO2013039477A8 (en) Non-invasive methods of detecting target molecules
WO2011097301A3 (en) METHODS AND COMPOSITIONS FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH TNF-α INHIBITOR
WO2011079902A3 (en) Biological inhibitors of ror1 capable of inducing cell death
WO2012116331A3 (en) Methods and systems for haplotype determination
BRPI0919377A2 (en) isolated antibody or antigen-binding fragment of the same, isolated nucleic acid, vector, host cell, pharmaceutical composition, method of producing said antibody or fragment, use thereof, and composition comprising said antibody or fragment
WO2015058008A3 (en) Enhanced nucleic acid identification and detection
GB201020995D0 (en) Biological materials and uses thereof
BR112014000263A2 (en) isolated antibody or antigen binding fragment thereof, nucleic acid molecule and pharmaceutical composition
WO2014005125A3 (en) Fluorescent compounds and uses thereof
WO2012061502A3 (en) Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof
UA105073C2 (en) Anti-fractalkine antibody, composition and method for treating inflammatory disorders
WO2009032316A3 (en) Genetic polymorphisms associated with rheumatoid arhritis, methods of detection and uses thereof
WO2012058220A3 (en) Anti-sod1 antibodies and uses thereof
WO2011127001A3 (en) Quantum dot-based optical sensors for rapid detection and quantitative analysis of biomolecules and biological materials
WO2011100752A3 (en) Methods and materials for assessing rna expression
WO2017041063A3 (en) Compositions and methods for identifying genetic predisposition to obesity and for enhancing adipogenesis
WO2006110358A3 (en) Methods and compositions for introducing biopolymers into cells
WO2008118415A3 (en) Genetic polymorphisms associated with coronary events and drug response

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11791711

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11791711

Country of ref document: EP

Kind code of ref document: A2